CI values of SU6668 with paclitaxel on endothelial and smooth muscle cells
| Cell line | Drugs | CI | ||||
|---|---|---|---|---|---|---|
| IC30 | IC50 | IC70 | ||||
| HUVEC | SU6668 + PTX | 0.35 ± 0.09 | 0.45 ± 0.09 | 0.57 ± 0.06 | ||
| HMVEC | SU6668 + PTX | 0.25 ± 0.14 | 0.39 ± 0.23 | 0.34 ± 0.10 | ||
| AoSMC | SU6668 + PTX | 0.40 ± 0.02 | 0.47 ± 0.11 | 0.58 ± 0.11 | ||
NOTE: The CI was evaluated for the combination of SU6668 with paclitaxel at IC30, IC50, and IC70 of each drug for HUVEC/HMVEC/AoSMC after 72-hour exposure (experiment as in Fig. 1). The CI was calculated as described in Materials and Methods and evaluated such that CI < 1 is synergism, CI > 1 is antagonism, and CI = 1 is additivity. Data are expressed as mean ± SE of all available pairs of concentrations producing the indicated growth inhibition and are representative of one experiment, repeated at least thrice.
Abbreviation: PTX, paclitaxel.